Research and real-world evidence support the use across a range of leukemias and lymphomas and demonstrate utility in multiple tissue types, including blood and bone marrow Late breaker presentation of CANDOR study includes secondary endpoint of improved NGS MRD negative Complete Re...

Adaptive Biotechnologies Corp (ADPT) Q3 2019 Earnings Conference Call November 12, 2019 16:30 ET Company Participants Carrie Mendivil - IR Chad Robins - CEO & Co-Founder Julie Rubinstein - President Chad Cohen - CFO Harlan Robins - Chief Scientific Officer & Co-Founde...

Adaptive Biotechnologies (NASDAQ: ADPT ): Q3 GAAP EPS of -$0.11 beats by $0.20 . More news on: Adaptive Biotechnologies Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...